	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M PR	12M PR	12M PR	12M PR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	212.91	277.84	311.64	385.37	530.05	460.94	570.37	696.49	827.88
Cost of Operating Revenue	148.58	162.86	155.91	147.30	223.87	218.80	273.33	268.92	282.44
Gross Profit	64.34	114.98	155.73	238.06	306.18	242.14	297.04	427.57	545.44
Gross Margin	30.2	41.4	50.0	61.8	57.8	52.5	52.1	61.4	65.9
Total Operating Expenses	196.19	216.74	219.19	224.67	326.05	337.10	406.48	447.21	562.24
Operating Profit	16.72	61.10	92.45	160.70	204.00	123.84	163.89	249.27	265.64
Operating Margin	7.9	22.0	29.7	41.7	38.5	26.9	28.7	35.8	32.1
Financing Income/(Expense) - Net	-7.52	-11.31	-5.12	2.78	2.89	6.43	6.25	2.33	-1.89
Profit before Taxes	14.46	57.10	96.23	167.39	207.24	123.49	165.69	248.48	274.78
Income Taxes	5.74	17.68	22.82	43.56	55.44	33.63	46.58	60.52	65.66
Profit after Tax	8.73	39.42	73.40	123.83	151.81	89.86	119.11	187.96	209.12
PAT Margin	4.1	14.2	23.6	32.1	28.6	19.5	20.9	27.0	25.3
EPS - Basic - ex Extraordinary Items	1.08	4.90	9.12	15.39	18.86	11.16	14.80	23.35	25.98
EPS - Diluted - ex Extraordinary Items	1.08	4.90	9.12	15.39	18.86	11.16	14.80	23.35	25.98
EBIT	16.72	61.10	92.45	160.70	204.00	123.84	163.89	249.27	265.64
EBITDA	22.06	66.53	98.83	167.46	214.12	135.65	179.72	269.72	294.05
EBITDA Margin	10.4	23.9	31.7	43.5	40.4	29.4	31.5	38.7	35.5

Balance Sheet

Abridged

Understanding Balance Sheet

Supriya Lifescience Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2018 Mar 31	2019 Mar 31	2020 Mar 31	R 2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	PR	PR	PR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	120	133	198	265	498	465	398	437	532
Long-Term Investments	0	0	0	0	0	25	64	63	99
Property Plant & Equipment - Net	125	118	135	177	232	328	457	599	723
Total Non-Current Assets	126	120	138	180	237	355	523	675	825
Total Assets	245	253	336	445	735	820	921	1,112	1,357
Total Current Liabilities	146	135	155	146	100	96	77	82	121
Long Term Debt	35	11	5	2	5	5	5	5	5
Total Non-Current Liabilities	45	24	32	31	19	25	29	33	38
Total Liabilities	191	159	187	177	119	121	106	116	159
Total Shareholders' Equity	55	94	149	269	616	699	815	997	1,198
Total Equity	55	94	149	269	616	699	815	997	1,198
Total Liabilities & Equity	245	253	336	445	735	820	921	1,112	1,357

Cash Flow

Abridged

Understanding Cash Flow Statement

Supriya Lifescience Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2018 Mar 31	2019 Mar 31	2020 Mar 31	R 2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M PR	12M PR	12M PR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	16.65	46.29	75.50	143.81	156.57	108.24	140.48	210.93	242.72
Working Capital - Increase/(Decrease)	0.80	-6.80	36.60	-66.82	-104.35	-35.64	-17.14	-38.36	-47.50
Net CF from Operating Activities	17.45	39.49	112.11	77.00	52.21	72.60	123.34	172.56	195.22
Capital Expenditures - Net	4.71	-4.76	24.52	46.80	59.82	107.90	145.66	162.38	152.23
Net CF from Investing Activities	-4.71	4.83	-24.52	-46.80	-59.82	-133.15	-184.16	-161.82	-187.52
Dividends Paid - Cash - Total	-	-	17.65	3.96	4.39	4.83	4.83	6.44	8.05
Stock - Issuance/(Retirement) - Net	-	-	-	-	200.00	-	-	-	-
Debt - LT & ST - Issuance/(Retirement) - Total	-9.71	-40.54	-7.63	-11.67	-49.37	-4.95	-16.98	-0.11	0.06
Net Cash Flow from Financing Activities	-9.71	-40.54	-25.27	-15.62	146.24	-9.78	-21.81	-6.55	-7.99
Free Cash Flow to Equity	3.03	3.72	79.95	18.53	-56.98	-40.25	-39.30	10.08	43.04
Free Operating CF net dividend	12.52	32.55	69.94	24.80	-12.08	-40.68	-27.15	3.75	34.94
Free Operating CF	12.52	32.55	87.58	28.75	-7.69	-35.85	-22.32	10.19	42.99

Business Segment Analysis

FY End:

Mar 25

Supriya Lifescience Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Active Pharmaceuticals Ingredients(API) (100.0%)₹ 162.38 Cr

Revenue / Sales

Active Pharmaceuticals Ingredients(API) (100.0%)₹ 696.49 Cr

Assets

Active Pharmaceuticals Ingredients(API) (100.0%)₹ 1,112.31 Cr

Operating Income

Active Pharmaceuticals Ingredients(API) (100.0%)₹ 249.27 Cr

Regional Segment Analysis

Supriya Lifescience Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

We don't have enough data to show regional segment analysis for Supriya Lifescience Ltd.

Historical Segment Analysis

Track how Supriya Lifescience Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31

Active Pharmaceuticals Ingredients(API)	5	7	25	48	60	108	146	162

Frequently Asked Questions

What is the revenue of Supriya Lifescience Ltd.?

The latest trailing twelve month revenue of Supriya Lifescience Ltd. is ₹ 827.88 Cr, reflecting a 1-year growth of 18.86% and a 3-year CAGR of 21.56%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Supriya Lifescience Ltd.?

The latest trailing twelve month net profit (PAT) of Supriya Lifescience Ltd. is ₹ 209.12 Cr, with a 3-year earnings CAGR of 32.51%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Supriya Lifescience Ltd.?

The trailing twelve month EBITDA of Supriya Lifescience Ltd. is approximately ₹ 265.64 Cr (based on an operating margin of 32.09%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Supriya Lifescience Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Supriya Lifescience Ltd. is 25.98. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Supriya Lifescience Ltd.?

The debt-to-equity ratio of Supriya Lifescience Ltd. stands at 0.00. The interest coverage ratio is 140.62x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Supriya Lifescience Ltd.?

The estimated book value per share of Supriya Lifescience Ltd. is 148.82 (derived from a P/B ratio of 5.57 and market price of ₹ 828.70), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Supriya Lifescience Ltd.?

The trailing twelve month operating cash flow of Supriya Lifescience Ltd. is ₹ 195.22 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Supriya Lifescience Ltd. report consolidated or standalone financials?

Supriya Lifescience Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.